Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2 EUR | +0.91% | +5.60% | +5.93% |
Valuation
Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
---|---|---|---|---|---|---|---|---|
Capitalization 1 | 83.25 | 126.5 | 210.1 | 142.5 | 133.1 | 115.2 | 115.2 | - |
Enterprise Value (EV) 1 | 67.16 | 104.6 | 184.1 | 142.5 | 134.4 | 108.8 | 134.3 | 129.7 |
P/E ratio | -71.9 x | -30.2 x | -53.1 x | -30.9 x | -33.1 x | -34.1 x | -18.1 x | -12.1 x |
Yield | - | - | - | - | - | - | - | - |
Capitalization / Revenue | 12.3 x | - | - | - | - | - | - | - |
EV / Revenue | 9.9 x | - | - | - | - | - | - | - |
EV / EBITDA | -24.2 x | -28.4 x | -44.4 x | -20.7 x | -25.3 x | -23.4 x | -34.6 x | 29.4 x |
EV / FCF | - | - | - | - | - | - | - | - |
FCF Yield | - | - | - | - | - | - | - | - |
Price to Book | - | - | - | - | - | - | - | - |
Nbr of stocks (in thousands) | 38,455 | 45,489 | 60,035 | 52,762 | 53,663 | 57,614 | 57,614 | - |
Reference price 2 | 2.165 | 2.780 | 3.500 | 2.700 | 2.480 | 2.000 | 2.000 | 2.000 |
Announcement Date | 2/15/19 | 2/24/20 | 2/23/21 | 2/7/22 | 2/17/23 | 2/26/24 | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
---|---|---|---|---|---|---|---|---|
Net sales 1 | 6.781 | - | - | - | - | - | - | - |
EBITDA 1 | -2.77 | -3.679 | -4.145 | -6.866 | -5.323 | -5.246 | -3.882 | 4.412 |
EBIT 1 | -10.18 | -3.969 | -4.339 | -17.61 | -21.45 | -19.25 | -21.47 | -20.36 |
Operating Margin | -150.2% | - | - | - | - | - | - | - |
Earnings before Tax (EBT) 1 | -3.712 | -4.576 | -4.339 | -6.939 | -5.492 | -4.634 | -6.356 | -1.352 |
Net income 1 | -1.177 | -3.809 | -3.435 | -4.639 | -4.233 | -3.415 | -5.427 | -0.4842 |
Net margin | -17.36% | - | - | - | - | - | - | - |
EPS 2 | -0.0301 | -0.0921 | -0.0659 | -0.0874 | -0.0750 | -0.0553 | -0.1103 | -0.1650 |
Free Cash Flow | - | - | - | - | - | - | - | - |
FCF margin | - | - | - | - | - | - | - | - |
FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
Dividend per Share | - | - | - | - | - | - | - | - |
Announcement Date | 2/15/19 | 2/24/20 | 2/23/21 | 2/7/22 | 2/17/23 | 2/26/24 | - | - |
Income Statement Evolution (Quarterly data)
Fiscal Period: December | 2019 S2 | 2020 S1 | 2021 Q1 | 2021 Q2 | 2021 S1 | 2021 Q3 | 2021 Q4 | 2021 S2 | 2022 Q1 | 2022 Q2 | 2022 S1 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 S1 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 S1 | 2024 Q3 | 2024 S2 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net sales 1 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBIT 1 | -1.623 | -7.688 | - | - | -3.318 | - | -5.145 | -14.18 | - | -1.759 | -3.363 | -4.998 | -5.891 | - | -4.841 | -2.471 | -4.244 | -4.551 | -4.923 | -5.202 | - | -5.508 | - |
Operating Margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Earnings before Tax (EBT) 1 | -1.945 | -2.155 | -1.682 | -1.575 | -3.318 | -1.541 | -2.116 | -3.497 | -1.661 | -1.753 | -3.437 | -0.694 | -1.49 | -1.614 | -1.179 | -3.272 | -0.7798 | -2.433 | -1.701 | -1.797 | -3.2 | -1.901 | -3.2 |
Net income 1 | -1.972 | -1.307 | -1.755 | 0.8 | -1.019 | -1.572 | -2.062 | -3.585 | -1.725 | 0.3394 | -1.298 | -0.6261 | -2.299 | -1.614 | 1.041 | -0.5682 | -1.063 | -1.638 | -1.787 | -1.883 | -3.2 | -2.007 | -1.2 |
Net margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EPS 2 | -0.0461 | -0.0259 | -0.0329 | 0.0168 | -0.0168 | -0.0257 | -0.0350 | -0.0700 | -0.0286 | 0.009820 | -0.0294 | -0.0101 | -0.0469 | -0.0273 | 0.0181 | -0.009030 | -0.0189 | -0.0270 | -0.0280 | -0.0280 | -0.1000 | -0.0325 | - |
Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Announcement Date | 2/24/20 | 7/22/20 | 5/7/21 | 7/29/21 | 7/29/21 | 10/28/21 | 2/7/22 | 2/7/22 | 5/5/22 | 7/22/22 | 7/22/22 | 11/2/22 | 2/17/23 | 5/10/23 | 7/24/23 | 7/24/23 | 10/27/23 | - | - | - | - | - | - |
Balance Sheet Analysis
Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
---|---|---|---|---|---|---|---|---|
Net Debt 1 | - | - | - | - | 1.36 | 7.32 | 19.1 | 14.5 |
Net Cash position 1 | 16.1 | 21.9 | 26.1 | - | - | - | - | - |
Leverage (Debt/EBITDA) | - | - | - | - | -0.256 x | -1.395 x | -4.92 x | 3.28 x |
Free Cash Flow | - | - | - | - | - | - | - | - |
ROE (net income / shareholders' equity) | - | - | - | - | - | - | - | - |
ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
Assets 1 | - | - | - | - | - | - | - | - |
Book Value Per Share | - | - | - | - | - | - | - | - |
Cash Flow per Share | - | - | - | - | - | - | - | - |
Capex 1 | 0.17 | 0.12 | 0.15 | 0.18 | 0.08 | 0.08 | 0.05 | 0.05 |
Capex / Sales | 2.5% | - | - | - | - | - | - | - |
Announcement Date | 2/15/19 | 2/24/20 | 2/23/21 | 2/7/22 | 2/17/23 | 2/26/24 | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+5.93% | 123M | |
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- ORY Stock
- Financials Oryzon Genomics S.A.